EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-SA 4.0

Cost-Effectiveness Analysis of Hemoptysis Therapies Among Hospitalized Patients at Persahabatan Hospital

Dendhi Bagus Andriyanto, Asri Nurfita Astuti, Asri Nurfita Astuti, Asri Nurfita Astuti, Asri Nurfita Astuti, Asri Nurfita Astuti, Asri Nurfita Astuti, Asri Nurfita Astuti, Asri Nurfita Astuti, Asri Nurfita Astuti, Asri Nurfita Astuti, Tri Kusumaeni

Persahabatan Respirology Journal · 13.07.2026 · 2 (1)

DOI: 10.67483/ss2dpc17 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Persahabatan Respirology Journal, online erschienen am 13.07.2026. Verfasst von Dendhi Bagus Andriyanto und 11 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Carbazochrome has not been included in the Indonesian National Formulary(FORNAS), which serves as a prescribing guideline for patients covered by the NationalHealth Insurance program (JKN). However, Persahabatan Hospital issued a Director’sDecree on January 18, 2024, permitting the use of carbazochrome for patients withmassive hemoptysis or for those who did not respond to tranexamic acid after three days oftreatment. This study aimed to analyze the cost-effectiveness of hemoptysis therapy inhospitalized patients at Persahabatan Hospital. A retrospective cohort study was conductedusing medical records of hospitalized patients with hemoptysis from January to June 2024.

Methods

Therapeutic effectiveness was assessed based on the time to bleedingcessation (days), while costs were calculated from total direct medical costs. Costeffectivenessanalysis was subsequently performed. The non-parametric Kruskal–Wallistest was used to compare therapeutic effectiveness and total direct medical costs amongthe three treatment groups.

Results

The results showed no significant differences in sex, age, diagnosis, therapeuticeffectiveness, or total direct medical costs among the treatment groups. However, therewas a significant difference in the proportion of patients with massive hemoptysis amongthe three groups (p=0.040), indicating differences in baseline disease severity.

Conclusion

There were no significant differences in sociodemographic profiles,therapeutic effectiveness, or total direct medical costs among the three treatment groups.

Zitieren

APA

Andriyanto, D. B., Astuti, A. N., Astuti, A. N., Astuti, A. N., Astuti, A. N., Astuti, A. N., Astuti, A. N., Astuti, A. N., Astuti, A. N., Astuti, A. N., Astuti, A. N., & Kusumaeni, T. (2026). Cost-Effectiveness Analysis of Hemoptysis Therapies Among Hospitalized Patients at Persahabatan Hospital. Persahabatan Respirology Journal, 2(1). https://doi.org/10.67483/ss2dpc17

Vancouver

Andriyanto DB, Astuti AN, Astuti AN, Astuti AN, Astuti AN, Astuti AN, et al. Cost-Effectiveness Analysis of Hemoptysis Therapies Among Hospitalized Patients at Persahabatan Hospital. Persahabatan Respirology Journal. 2026;2(1). doi:10.67483/ss2dpc17

BibTeX
@article{Andriyanto2026,
  author = {Andriyanto, Dendhi Bagus and Astuti, Asri Nurfita and Astuti, Asri Nurfita and Astuti, Asri Nurfita and Astuti, Asri Nurfita and Astuti, Asri Nurfita and Astuti, Asri Nurfita and Astuti, Asri Nurfita and Astuti, Asri Nurfita and Astuti, Asri Nurfita and Astuti, Asri Nurfita and Kusumaeni, Tri},
  title = {Cost-Effectiveness Analysis of Hemoptysis Therapies Among Hospitalized Patients at Persahabatan Hospital},
  journal = {Persahabatan Respirology Journal},
  year = {2026},
  volume = {2},
  number = {1},
  doi = {10.67483/ss2dpc17}
}
Kostenlos starten →